Transactions

Since our inception in August 2016 we have advised corporate clients and raised more than SEK 8 billion from global specialist investors, blue chip pension funds and renown mutual funds. Before taking on a fund-raising advisory assignment we perform extensive due diligence to make sure that the companies we work with are of such high quality that we can leverage our global network of sophisticated investors. We take pride in executing transactions to help allocating capital to promising new life-saving efforts.

AlzeCure

SEK 39m, rights issue
May 2024

BrainCool

SEK 86m, rights issue
May 2024

Oncopeptides

SEK 314m, rights issue
May 2024

Lipum

SEK 80m, rights issue
April 2024

Iconovo

SEK 33m, directed issue
February 2024

Medivir

SEK 129m, rights issue
December 2023

Cantargia

SEK 59m, directed issue
October 2023

Nanexa

SEK 75m, rights issue
October 2023

Senzime

SEK 117m, directed issue
September 2023

Toleranzia

SEK 43m, rights issue
September 2023

BrainCool

SEK 60m, directed issue
August 2023

Senzime

SEK 56m, directed issue
August 2023

Xspray

SEK 251m, rights issue
June 2023

Vicore Pharma

SEK 500m, directed issue
June 2023

BrainCool

SEK 31m, directed issue
December 2022

Vicore Pharma

SEK 200m, directed issue
December 2022

BrainCool

SEK 82m, rights issue
November 2022

Xspray

SEK 100m, directed issue
October 2022

Qlife Holding

SEK 50m, rights issue
October 2022

Nanologica

SEK 80m, rights issue
October 2022

Episurf

SEK 159m directed share issue
October 2021

Qlife

SEK 90m directed share issue
April 2021

Vicore Pharma

SEK 336m, directed share issue
February 2021

IRLAB Therapeutics

SEK 130m, directed share issue
December 2020

Episurf Medical

SEK 66m, directed share issue
November 2020

Xspray Pharma

SEK 265m, directed share issue
October 2020

Hansa Biopharma

SEK 1112m, directed share issue
July 2020

Vicore Pharma

SEK 185m, directed share issue
July 2020

Cantargia

SEK 410m, directed share issue
February 2020

Episurf Medical

SEK 140m, directed share issue and rights issue
February 2020

IRLAB Theraeputics

SEK 215m, directed share issue and rights issue
December 2019

Xspray

SEK 122m, directed share issue
December 2019

Vicore Pharma

SEK 125 M, directed share issue
November 2019

Asarina Pharma

SEK 48 M, directed share issue
October 2019

Calliditas Therapeutics

SEK 300 M directed share issue and secondary sale
July 2019

Xspray

SEK 92 M, directed share issue
December 2018

Vicore Pharma

SEK 160 M directed share issue
November 2018

Hansa Biopharma

SEK 675 M directed share issue and secondary sale
November 2018

Asarina Pharma

SEK 150 M, IPO
September 2018

Vicore Pharma

NA, M&A
June 2018

Integrative Research Laboratories

SEK 139 M, directed share issue
May 2018

Xspray

SEK 88 M, directed share issue
January 2018

Hansa Biopharma

SEK 545 M, directed share issue
November 2017

Infant Bacterial Therapeutics

SEK 545 M, directed share issue and rights issue
November 2017

Xspray

SEK 132 M, IPO
August 2017

Vicore Pharma

SEK 56 M, directed share issue
February 2017

Hansa Biopharma

SEK 185 M, directed share issue
November 2016
Rulla till toppen